Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Beijing Biotech
Beijing Biotech
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ohio State University Comprehensive Cancer Center
Emory University
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
University of Rochester
Dana-Farber Cancer Institute
Nanfang Hospital, Southern Medical University
University of Miami
Tulane University
Emory University
Vanderbilt-Ingram Cancer Center
Wake Forest University Health Sciences
Herlev Hospital
St. Anna Kinderkrebsforschung
Fate Therapeutics
Fate Therapeutics
Zealand University Hospital
Roswell Park Cancer Institute
The First Affiliated Hospital of Soochow University
Ottawa Hospital Research Institute
Zealand University Hospital
Wake Forest University Health Sciences
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Senlang Biotechnology Inc., Ltd.
Peking University People's Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Roswell Park Cancer Institute
Gilead Sciences
Seoul National University Hospital
Yale University
M.D. Anderson Cancer Center
Washington University School of Medicine
Wake Forest University Health Sciences
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
The Royal Bournemouth Hospital
St. Jude Children's Research Hospital
Rochester General Hospital
St. Antonius Hospital
Stony Brook University
Roswell Park Cancer Institute
Chiltern Pesquisa Clinica Ltda
Radboud University Medical Center
National Taiwan University Hospital